For connective tissue diseases, the multiplex assay is designed to rapidly detect and identify up to 1275 disease markers per hour. Seamless, microarray-internal calibration and quality control as ...
EYSINS, Switzerland, Feb. 3, 2025 /PRNewswire/ -- AliveDx announces the receipt of IVDR-CE mark for its MosaiQ AiPlex ® CTDplus multiplex assay. The multiplex assay enables a syndromic approach, ...
EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ — AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac Disease ...
The study suggests that long-term monitoring and patient management are crucial after COVID-19. Study: Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19.
Systemic autoimmune Rheumatic Diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, Systemic Sclerosis (also known as Scleroderma), Sjögren's syndrome, idiopathic inflammatory ...